The gut microbiome increasingly is recognized for its role in human health and disease. Initial evidence has indicated that gut microbial dysbiosis is associated with several pancreatic diseases. Although it is not known if these associations are causative, gut dysbiosis is hypothesized to mediate chronic proinflammatory changes in the pancreas. Further mechanistic and epidemiologic studies of the microbiome are needed. Ultimately, targeted modulation of the microbiota could have therapeutic value.
T he human gastrointestinal tract has a rich microbial community consisting of more than 10 14 microorganisms and more than 5,000,000 genes. 1, 2 Firmicutes and Bacteroidetes are the most prevalent bacteria, constituting 80% to 90% of the gut microbiota. 3 Gut microbiota play a major role in human physiology through effects on metabolism, modulation of the mucosal immune system, vitamin production, facilitation of digestion, and modulation of intestinal architecture. The gut microbiome influences the immune system through its effect on systemic metabolism effects as well as its antigenic effects. Normal gut bacteria play a crucial role in maintaining gut mucosal integrity. The interplay between the gut microbiota, immune system, and intestinal barrier limits the growth of pathogenic flora, 4 and disruption of this homeostasis leads to microbial imbalance. 5 The gut microbiome is known to have major effects on systemic metabolism, 6, 7 but there are thousands of metabolites in the plasma and in the gut, many of which remain uncharacterized. 7 A large portion of the variance in fecal metabolites can be explained by the composition of the fecal microbiome. 7, 8 Dysbiosis is associated with the pathogenesis of several gastrointestinal diseases (inflammatory bowel disease, irritable bowel syndrome), 9 as well as other diseases such as obesity, the metabolic syndrome, diabetes, [10] [11] [12] and pancreatic diseases including pancreatic cancer. 13, 14 The normal pancreas is not in direct contact with the gut microbiota and previously was not considered to have a microbiome of its own. However, gut flora can migrate into the pancreas and may influence the pancreatic microenvironment, even in subjects with an otherwise normal pancreas. 15 Gut microbiota alterations are found in pancreatic disease and may play a role in the pathogenesis of several pancreatic diseases including acute pancreatitis, chronic pancreatitis, and pancreatic cancer.
14 However, there is still only limited evidence supporting a causal relationship between gut dysbiosis and pancreatic diseases. Many common factors influence the composition of the human microbiome including diet, 16, 17 commonly used medications (eg, proton pump inhibitors, 18 metformin 19 ) , and genetics, [20] [21] [22] necessitating carefully controlled studies to evaluate relationships between the microbiome and disease. For this reason, many of the insights to date have come from animal models. In this review, we discuss relevant human and animal studies that have provided insights into the role of the gut microbiome in the pathogenesis of pancreatic diseases.
Acute Pancreatitis
Acute pancreatitis is among the most common gastrointestinal disorders requiring hospitalization, with an annual incidence of 13 to 45 cases per 100,000 persons in the United States. 23, 24 Regardless of the etiology, acute pancreatitis is the result of premature intra-acinar activation of trypsinogen and other proteolytic enzymes resulting in pancreatic acinar injury, up-regulation of proinflammatory mediators, release of cytokines, systemic inflammatory response, and microcirculatory injury. 25 In the setting of acute pancreatitis, microcirculatory injury and hypovolemia can lead to gut mucosal ischemia and reperfusion injury resulting in loss of gut barrier integrity and translocation of gut flora causing local and systemic infections. 26 In a meta-analysis of 18 studies, Wu et al 27 found that 59% of patients with acute pancreatitis have gut barrier dysfunction. In 1 study, circulating bacterial DNA representative of gut microbiota was found in 68.8% of patients with acute pancreatitis. 28 Circulating bacteria likely contribute to the mortality from acute pancreatitis by causing infection within necrotic areas of the pancreas. Mortality in patients with infected pancreatic necrosis and organ failure is approximately double that found in patients with sterile pancreatic necrosis and organ failure. 29 The microbial composition of infected pancreatic necrosis previously was dominated by gram-negative flora of gastrointestinal origin, such as Enterobacteriaceae. However, in recent years, the widespread use of prophylactic antibiotics have shifted the dominant flora to Staphylococcus, Enterococcus, and Candida. 30 Patients at higher risk of infected pancreatic necrosis are those who have been treated previously with antibiotics. Although patients with infected pancreatic necrosis have a higher mortality rate, the microbial spectrum of infected necrosis does not appear to influence mortality. 31 Necrotizing pancreatitis is known to impair gastrointestinal motility and in animal models results in small intestinal bacterial overgrowth (SIBO). In these models, duodenal bacterial overgrowth is associated with bacterial translocation and pancreatic infection. 32 In a rat model of necrotizing pancreatitis, bacterial translocation and subsequent infected pancreatic necrosis was found to be more frequent from the small bowel than the colon. 33 Experimental necrotizing pancreatitis induces proinflammatory cytokines and reduces antimicrobial peptide expression (a-defensins and lysozyme) in the distal ileum. 34 These antimicrobial peptides help maintain gut microbiota homeostasis and barrier function. 35 Antimicrobial peptides also are secreted by pancreatic acinar cells. Knockout of the Ca 2þ channel Orai1 in pancreatic acinar cells (Orai1 -/-) in mice reduced secretion of cathelicidin-related peptide, the major antimicrobial secreted by the pancreas, and resulted in increased small-bowel and colonic bacterial colonization, increased intestinal permeability and bacterial translocation, with resultant systemic infection and mortality. Mortality was reduced with antibiotics, short-chain free fatty acids, and synthetic cathelicidin-related peptide. 36 Interestingly, in pancreatic acinar cells, sensing of bacterial antigens by pathogen recognition receptors such as Toll-like receptors and the nucleotide binding oligomerization domain (NOD)-like receptors are thought to contribute to the pathogenesis of pancreatitis. Pancreatitis in mice can develop by chronic low-dose cerulein stimulation with NOD1 agonist stimulation, effects that are prevented in NOD1 knockout mice. 37 NOD1 can bind to peptidoglycan peptides in pancreatic acinar cells. 38 Patients with acute pancreatitis are more likely than healthy volunteers to have gut dysbiosis (higher Enterobacteriaceae and Enterococcus populations, lower Bifidobacteria). 39 These preclinical and human studies that implicate a role for intestinal dysbiosis in the pathogenesis and severity of acute pancreatitis raise the question of whether modulating the gut microbiome might be beneficial. Altering the acute pancreatitis-associated microbiota with physiological gut microbiota using broad-spectrum antibiotics and antimicrobial peptides might be expected to improve outcome. Benign physiological gut microbiota such as Lactobacillus alone and Bifidobacterium are thought to help maintain gut barrier function and limit the growth of pathogenic flora. The potential value of using probiotics for patients with severe acute pancreatitis has been evaluated in randomized controlled trials and summarized in a Cochrane review and a meta-analysis. 40, 41 Overall, probiotics have been shown to have no significant beneficial or adverse effects in patients with severe acute pancreatitis. One caveat is that these trials had significant heterogeneity with respect to patient characteristics and probiotic regimens. One of these trials, conducted in The Netherlands, the Probiotics in Pancreatitis Trial, 42 randomized 296 patients with predicted severe acute pancreatitis to a multispecies probiotic mixture containing 2 different Bifidobacterium species, 3 different Lactobacillus species, and 1 Lactococcus species vs placebo. The infectious complications were similar among the 2 groups, but the probiotic group had a higher mortality rate (16% vs 6%) and incidence of bowel ischemia (6% vs 0%) compared with the placebo group. The high load of probiotic mixture used in this study was suspected to be a cause of the increased mortality in the treated group. 43 These studies highlight the challenges of trying to beneficially manipulate the gut microbiome in the setting of acute pancreatitis.
Chronic Pancreatitis
Several studies have evaluated the gut microbiome in patients with chronic pancreatitis. 44 Evidence for gut microbial dysbiosis is suggested by the frequent observation of SIBO in patients with chronic pancreatitis. SIBO is thought to be more likely to arise in patients with chronic pancreatitis as a result of reduced pancreatic synthesis of antimicrobial peptides, impaired motility, abnormal chyme formation in the small intestinal lumen, and from reduced alkalization resulting from reduced bicarbonate-rich pancreatic secretory capacity. 45, 46 SIBO can exacerbate pancreatic exocrine insufficiency, suggesting that treatment of SIBO would help patients with pancreatic exocrine insufficiency. 47 In a meta-analysis by Capurso et al, 48 the mean prevalence of SIBO in patients with chronic pancreatitis was reported to be 36% (95% CI, 17%-60%), although significant heterogeneity between studies was noted. In a subsequent study, Jandhyala et al 49 examined 16 patients with chronic pancreatitis, 14 with chronic pancreatitis with diabetes and 10 healthy controls. Phyla abundances were different in the 3 patient groups, with reductions in the abundance of Bacteroidetes and increases in the Firmicutes to Bacteroidetes ratio among patients with chronic pancreatitis. There was a significant reduction in Faecalibacterium prausnitzii and Ruminococcus bromii between the control, chronic pancreatitis without diabetes, and chronic pancreatitis with diabetes groups. F prausnitzii is known to contribute to intestinal barrier homeostasis and integrity. 50, 51 Plasma endotoxin was detected in many of these patients and correlated negatively with glycemic status, indicating that gut microbial dysbiosis was associated with the metabolic alterations of chronic pancreatitis. 49 Additional studies are needed to evaluate the role of gut dysbiosis in the setting of chronic pancreatitis.
Pancreatic Cancer
The incidence of pancreatic cancer has been increasing and is expected to be the second leading cause of death in the United States by 2030. 52 The reasons for this increase in incidence are not fully understood but could in part be related to an increased incidence of known risk factors for pancreatic cancer including obesity, diabetes, and the metabolic syndrome. Obesity and diabetes are known to be associated with changes in the gut microbiome, [10] [11] [12] and some of their metabolic consequences could be mediated in part through effects on the gut microbiome. Chronic pancreatitis is also a risk factor for developing pancreatic cancer, with the risk increasing with the duration of disease. [53] [54] [55] Because gut dysbiosis has been postulated to contribute to chronic pancreatic inflammation, it also may contribute to the pathogenesis of pancreatic cancer in the setting of chronic pancreatitis.
Gut dysbiosis has been hypothesized to promote the development of many types of cancer through systemic mechanisms, particularly metabolic changes that can influence precancerous cells and immune cells. 56 For example, short-chain fatty acids produced in the gut with the help of the gut microbiome have metabolic effects on immune cells. 57 In the colon, adherent bacteria such as Bacteroides fragilis are thought to promote adenomas and cancers because they produce enterotoxins that have tumorigenic effects including effects on signaling, cell adhesion molecules, and cytokine alterations. 58, 59 Consistent with their role in modulating the immune response, gut bacterial profiles are recognized as influencing the immune response directed toward tumors. 15, 60 Several studies have shown that gut microbiome profiles influence the immune therapy response to checkpoint inhibitor therapy. [61] [62] [63] Several studies have evaluated the influence of the microbiome on the pathogenesis of pancreatic cancer (summarized in Table 1 ). For example, several studies have found differences in the oral microbial flora between patients with pancreatic cancer compared with controls. Fan et al 64 and Michaud et al 65 found higher levels of Porphyromonas gingivalis in patients with pancreatic cancer than controls; the highest concentration of P gingivalis was associated with a 2-fold increase in pancreatic cancer risk, although a smaller study did not find this association. 66 P gingivalis is an important contributor to periodontal disease and has been postulated to cause systemic inflammation. 67 Other oral microbial differences found between patient groups with pancreatic cancer, chronic pancreatitis, and healthy controls were described by Farrell et al. 68 Because these were case/control studies, it is not yet clear if these microbial changes contributed to disease pathogenesis or were merely a consequence of the disease. Recent studies also have identified bacteria within the tumor microenvironment of human pancreatic cancers 15 and within other tumors. 69 The bacteria identified in human pancreatic cancers are representative of the major genus of gut bacteria such as Proteobacteria. 15, 69 Recent studies in genetically engineered mouse models of pancreatic neoplasia have shed additional light on the role of gut bacteria in pancreatic tumorigenesis. By using the Ptf1a Cre ; LSL-Kras G12D (KC) and Ptf1a Cre , LSL-Kras G12D , Trp53 R172H (KPC) mouse models of pancreatic neoplasia, Pushalkar et al 15 found that oral antibiotics protected against neoplastic progression. They also found repopulating germ-free KC mice with feces from pancreatic cancer-bearing KPC mice or with Bifidobacterium pseudolongum accelerated disease progression. B pseudolongum also could be detected within the pancreata of treated mice. Changes in the gut microbiome resulted in changes in immune cells within the tumor microenvironment. Microbial ablation led to a reduction in immunosuppressive CD206
þ M2-like tumor-associated macrophages with a concomitant increase in tumorprotective M1-like tumor-associated macrophages, and an increase in the CD8/CD4 ratio within the tumor microenvironment, changes that reversed with repopulation of the microbiome. Similarly, another recent study using wild-type C57BL/6J, Rag1 knock-out (lacked mature T and B cells), KPC and Pten fl/fl mice showed that gut microbial depletion with antibiotics resulted in an increase in Th1 (interferon g
cells in the tumor microenvironment and a reduction in pancreatic tumor burden. 70 Experimental models also have found that intratumoral bacteria alter the metabolism of nucleoside chemotherapeutics such as gemcitabine. 69, 71 Bacteria also are detected in pancreatic cyst fluids, including cysts associated with an intraductal papillary mucosal neoplasm as well as non-neoplastic cysts, but the significance of these bacteria is not clear. 72 Despite these intriguing studies, the evidence that bacteria within the pancreas contributes to human pancreatic cancer pathogenesis still is limited.
Conclusions
Gut microbial dysbiosis is thought to contribute to the pathogenesis of pancreatic diseases (Figure 1) . Much of the evidence for this comes from animal models and these models will continue to be valuable for testing hypotheses. There still is much to understand about the causes and consequences of gut microbial dysbiosis as well as the contributions played by alterations in the abundance of different species. There are many largescale efforts underway to characterize the human microbiome, the dietary, genetic, pathologic, and pharmacologic variables that influence the human microbiome and its metabolic effects. Unraveling these associations is a necessary step toward better understanding the role of the microbiome in human pancreatic disease. Evaluating the gut microbiome of patients at risk of pancreatic disease in prospective studies is necessary to better understand the role of gut dysbiosis in human pancreatic disease pathogenesis.
